摘要
首仿药的专利挑战Paragraph Ⅳ制度及180天市场独占期的规定,在一定程度上保护了首仿药企业的市场优势。本文梳理了2018年上旬美国专利挑战成功首仿的品种,通过总结和个案分析,为中国制药工业的发展提出了通过建立首仿药目录和待仿品种清单完善仿制药数据系统、建立REMS专业性网站、充实中国上市药品目录集数据库和优选首仿药品种4项策略。
The Paragraph Ⅳ system for first generics and the 180-day exclusive market period,to a certain extent protecting the market advantages of first generics companies. This paper reviews the first generics in the United States in early 2018. Through summary and case analysis,it is proposed to perfect the generic drug data system by establishing the first generic drug catalogue and the list of generic varieties to be imitated,to establish the REMS professional website,to improve the database of the Chinese listed drug catalogue and the preferred the first generics screening for the development of Chinese pharmaceutical industry.
引文
[1]王莹,顾东蕾,邹涛,等.英国药品补充保护证书[J].中国新药杂志,2018,27(6):626-633.
[2]刘应梅,许慧.葛兰素集团在吸入性糖皮质激素治疗哮喘领域的专利布局分析[J].今日药学,2018,28(6):421-425.
[3]陈小梦,左子欣,孙亚新,等.美国“Bolar例外”及首仿药制度的研究及对我国的启示[J].中国药事,2018,32(6):732-736.
[4]朱精兵,顾东蕾.2014年美国首仿药数据行为剖析[J].中国新药杂志,2015,24(24):2775-2778.
[5]武莹,顾东蕾,戴静雪.酪氨酸激酶抑制剂在我国专利布局研究[J].中国新药杂志,2018,27(7):729-737.
[6]Novartis International AG.Condensed Interim Financial ReportSupplementary Data[R].2017.
[7]Indivior Inc Annual Report[R].2017.
[8]Voyager88.美国仿制药的钱真那么好赚?喝多了异想天开吧?![EB/OL].(2018-08-24).[2018-08-27].https://mp.weixin.qq.com/s/CnaVZj8JEV7-voiIKEb9pQ.
[9]药神没有告诉你的仿制药“秘密”[EB/OL].(2018-07-17)[2018-08-27].http://www.instrument.com.cn/news/20180717/467636.shtml.
[10]马飞.首仿药审评“快进”配套难题待解[N].医药经济报,2016-07-27(001).
[11]冯霄婵,杨悦.美国药品审评创仿平衡机制研究[J].中国药学杂志,2018,53(11):938-944.
[12]鲍程程,王宏伟,杨悦.FDA风险评估与减低策略实施与借鉴的思考[J].中国药物警戒,2017,14(5):283-288.